Loading live market data…

Aquestive Therapeutics, Inc.

NASDAQ:AQST

$4.04 USD

-$0.02 (-0.49%)

Volume
901.36K
Average Volume
1.79M
Market Capitalization
$401.2M
P/E Ratio
-6.62
Dividend Yield
0.00%
Price Target
$9.00
Year High
$7.55
Year Low
$2.93
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.10

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Daniel Barber
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Current Symbol AQST
CUSIP 03843E104
CIK 0001398733
Web https://www.aquestive.com
Phone 908 941 1900
Currency USD
Employees 147
Country US

Liquidity

Debt-to-Equity Ratio -3.92
Payout Ratio 0.00
Current Ratio 4.10
Quick Ratio 3.85
Cash Ratio 3.49

Sales & Book Value

Annual Sales $44.54M
Price / Sales 7.98
Cash Flow -0.36
Price / Cash Flow -9.05
Price / Book -14.55

Price Target and Rating

Average Stock Price Forecast $9.00
High Stock Price Forecast $12.00
Low Stock Price Forecast $6.00
Forecast Upside/Downside -55.11%
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 10 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.76
Trailing P/E Ratio -6.62
PEG Ratio 0.55
P/E Growth 0.55
Net Income $-83.78M
Net Margin -137.08%
Pretax Margin -137.08%
Return on Equity 190.87%
Return on Assets -48.83%

Financials Score

AltmanZ Score -3.16
Piotroski Score 2.00
Working Capital 98.43M
Total Assets 141.12M
Ebit -52.15M
Market Cap 402.28M
Total Liabilities 175.18M

Poll Results

About Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Liberva ... nt, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

2026-07-07 07:00:00

WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host 1x1 investor meetings on July 14, 2026.

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

2026-06-24 08:37:04

Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

2026-05-14 11:07:09

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics Q1 Earnings Call Highlights

2026-05-14 10:09:56

Aquestive Therapeutics NASDAQ: AQST said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quarter revenue and a narrower net loss.

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

2026-05-13 19:00:22

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

2026-05-13 18:15:57

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.24 per share a year ago.

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-13 16:01:00

WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic business update.

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

2026-05-12 09:31:25

WARREN, N. J. , May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new $150 million debt facility with funds managed by Oaktree Capital Management, L.

Frequently Asked Questions

What is the current Aquestive Therapeutics, Inc. (AQST) stock price?

Aquestive Therapeutics, Inc.(NASDAQ:AQST) stock price is $4.04 in the last trading session. During the trading session, AQST stock reached the peak price of $7.55 while $2.93 was the lowest point it dropped to. The percentage change in AQST stock occurred in the recent session was --0.49% while the dollar amount for the price change in AQST stock was -$-0.02.

AQST's industry and sector of operation?

The NASDAQ listed AQST is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AQST?

Lori J. Braender BSBA | Corporate Secretary
Sherry Korczynski | Chief Commercial Officer
Melina T. Cioffi | Senior Vice President of Regulatory Affairs
A. Ernest Toth Jr. | Senior VP & CFO
Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer

How many employees does AQST have?

Number of AQST employees currently stands at 147. AQST operates from 30 Technology Drive, Warren, NJ 07059, US.

Link for AQST official website?

Official Website of AQST is: https://www.aquestive.com

How do I contact AQST?

AQST could be contacted at phone #908 941 1900 and can also be accessed through its website. AQST operates from 30 Technology Drive, Warren, NJ 07059, US.

How many shares of AQST are traded daily?

The average number of AQST shares traded daily for last 3 months was 1.79M.

What is the market cap of AQST currently?

The market value of AQST currently stands at $401.2M with its latest stock price at $4.04